MONTECUCCO, CARLOMAURIZIO
 Distribuzione geografica
Continente #
NA - Nord America 25.647
AS - Asia 19.140
EU - Europa 13.921
SA - Sud America 2.585
Continente sconosciuto - Info sul continente non disponibili 1.175
AF - Africa 648
OC - Oceania 32
Totale 63.148
Nazione #
US - Stati Uniti d'America 25.037
CN - Cina 9.001
SG - Singapore 4.341
IE - Irlanda 3.266
HK - Hong Kong 2.059
BR - Brasile 1.923
VN - Vietnam 1.777
DE - Germania 1.746
UA - Ucraina 1.714
RU - Federazione Russa 1.576
FI - Finlandia 1.483
IT - Italia 979
FR - Francia 894
SE - Svezia 866
GB - Regno Unito 674
IN - India 404
BD - Bangladesh 339
ZA - Sudafrica 337
CA - Canada 318
AR - Argentina 241
IQ - Iraq 156
JP - Giappone 154
MX - Messico 124
TR - Turchia 124
AT - Austria 107
CO - Colombia 106
EC - Ecuador 105
NL - Olanda 93
ES - Italia 92
PK - Pakistan 92
PL - Polonia 92
ID - Indonesia 85
SA - Arabia Saudita 80
BE - Belgio 68
VE - Venezuela 65
MA - Marocco 59
MY - Malesia 58
UZ - Uzbekistan 54
PH - Filippine 53
CZ - Repubblica Ceca 50
TN - Tunisia 44
AE - Emirati Arabi Uniti 43
CL - Cile 43
IR - Iran 41
KE - Kenya 39
EG - Egitto 38
LT - Lituania 36
NP - Nepal 35
PY - Paraguay 35
JO - Giordania 28
JM - Giamaica 27
PE - Perù 27
CR - Costa Rica 26
AU - Australia 25
IL - Israele 25
ET - Etiopia 23
DZ - Algeria 22
AZ - Azerbaigian 21
KZ - Kazakistan 21
RO - Romania 21
SN - Senegal 21
AL - Albania 20
MU - Mauritius 19
DO - Repubblica Dominicana 18
TT - Trinidad e Tobago 18
UY - Uruguay 18
BO - Bolivia 17
OM - Oman 16
TH - Thailandia 16
KR - Corea 14
PA - Panama 14
HU - Ungheria 13
LV - Lettonia 13
DK - Danimarca 12
KG - Kirghizistan 12
LB - Libano 12
PS - Palestinian Territory 12
GR - Grecia 11
HN - Honduras 11
NI - Nicaragua 11
SY - Repubblica araba siriana 11
BG - Bulgaria 10
EU - Europa 10
RS - Serbia 10
PT - Portogallo 9
SK - Slovacchia (Repubblica Slovacca) 9
BY - Bielorussia 8
KW - Kuwait 8
MK - Macedonia 8
NG - Nigeria 8
SV - El Salvador 8
CH - Svizzera 7
GE - Georgia 7
GT - Guatemala 7
HR - Croazia 7
LK - Sri Lanka 7
MD - Moldavia 7
NO - Norvegia 7
NZ - Nuova Zelanda 5
A2 - ???statistics.table.value.countryCode.A2??? 4
Totale 61.867
Città #
Dublin 3.242
Chandler 3.007
San Jose 2.813
Ashburn 2.293
Jacksonville 2.266
Singapore 2.124
Hong Kong 2.014
Nanjing 1.841
Dallas 1.700
Beijing 1.346
Boardman 1.005
Council Bluffs 896
Nanchang 758
Princeton 720
Lawrence 662
Lauterbourg 648
Wilmington 622
Ho Chi Minh City 618
Helsinki 593
Los Angeles 583
Changsha 556
Shenyang 553
Hebei 539
Medford 471
Munich 436
Jiaxing 426
New York 423
Hanoi 419
Hangzhou 322
Tianjin 309
Shanghai 288
Johannesburg 283
Redondo Beach 282
Moscow 280
Ann Arbor 276
Buffalo 265
Milan 237
Santa Clara 218
São Paulo 172
Houston 163
Orem 152
Woodbridge 146
Pavia 144
Turku 144
Norwalk 132
Tokyo 131
Da Nang 119
Chicago 108
Verona 105
Seattle 103
Toronto 102
Brooklyn 96
Frankfurt am Main 96
Montreal 87
Fairfield 81
London 80
Warsaw 79
Falkenstein 78
Chennai 77
Vienna 75
The Dalles 73
Guangzhou 70
Columbus 69
Brussels 68
San Francisco 68
Denver 66
Atlanta 65
Rio de Janeiro 65
Haiphong 62
Zhengzhou 58
Jinan 56
Stockholm 56
Nuremberg 55
Boston 54
Washington 54
Phoenix 53
Baghdad 52
Manchester 49
Pune 49
Ningbo 48
Amsterdam 46
Belo Horizonte 46
Tashkent 46
Poplar 44
Rome 43
Brasília 41
Mexico City 41
Porto Alegre 40
Ankara 39
Dhaka 38
Quito 37
Des Moines 36
Piscataway 35
Mumbai 34
Kunming 33
Biên Hòa 32
New Delhi 32
Jeddah 31
Lahore 31
Curitiba 30
Totale 40.749
Nome #
Timing of onset affects arthritis presentation pattern in antisynthetase syndrome 268
Ultrasonographic evaluation of entheses in patients with spondyloarthritis: a systematic literature review 198
The role of Trimethoprim/sulfametoxazole in reducing relapses and risk of infec-tions in ANCA-associated vasculitis: a meta-analysis 177
Anterior chest wall arthritis and osteitis associated with Sneddon-Wilkinson disease 170
Analysis of bronchoalveolar lavage fluid proteome from systemic sclerosis patients with or without functional, clinical and radiological signs of lung fibrosis. 167
2-DE and LC-MS/MS for a Comparative Proteomic Analysis of BALf from Subjects with Different Subsets of Inflammatory Myopathies 159
Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study 158
[Italian Society of Rheumatology (SIR) recommendations for performing arthrocentesis.] 157
-238 and +489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis. 155
B cells in rheumatoid arthritis. 155
Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies 155
Assessment of synovitis to predict bone erosions in rheumatoid arthritis 153
Milwaukee shoulder syndrome(artropatia destruente apatite-associata):aspetti terapeutici 151
BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis 151
Allopurinol Mouthwashes In Methotrexate-induced Stomatitis 148
B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers 147
Anti-neutrophil cytoplasmic antibodies (ANCA) ( Review ) [Anticorpi anticitoplasma dei neutrofili (ANCA)] 145
Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis 142
Prevalence of undiagnosed autoimmune rheumatic diseases in the first trimester of pregnancy. Results of a two steps strategy using a self administered questionnaire and autoantibody testing. 142
A case of adult onset Still's disease treated with infliximab - Reply 141
Antinuclear antibodies in systemic sclerosis 140
Disease-related malnutrition in systemic sclerosis: Evidences and implications 140
Cardiovascular comorbidities relate more than others with disease activity in rheumatoid arthritis 140
Nutritional parameters associated with prognosis in non-critically ill hospitalized COVID-19 patients: The NUTRI-COVID19 study 140
Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis 140
In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: Comparison of two cohorts treated according to different treat to target protocols 139
Prognostic value of antisynthetase antibodies in patients affected by polymiositis/dermatomyositis with interstitial lung disease 138
Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: A European Scleroderma Trials and Research (EUSTAR) analysis 138
[Health-related quality of life in patients with rheumatoid arthritis: assessment by a Italian version of the Arthritis Impact Measurement Scales, Version 2 (AIMS2)]. 137
DMARDS and infections in rheumatoid arthritis 136
An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations 136
Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single centre cohort study 135
A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study 134
Cobalt hip prosthesis intoxication mimicking an autoimmune disease 134
Is it really infective endocarditis? Distinguishing systemic vasculitis from its mimics 134
Systemic vasculitis and pregnancy: A multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies 133
Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. 133
Nailfold capillaroscopy characteristics of antisynthetase syndrome and possible clinical associations: Results of a multicenter international study 133
COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine 131
Proliferation characteristics and polyploidization of cultured myofibroblasts from a patient with fibroblastic rheumatism 130
Autoantibodies to RNA-polymerases in Italian patients with systemic sclerosis. 130
Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus. 130
Clinical, genetic amd immunologic analysis of a family affected by Ozena. 129
A comparison of the sensitivity of diagnostic criteria for polymyalgia rheumatica. 129
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins 129
Cytokine profile of bronchoalveolar lavage in systemic sclerosis with interstitial lung disease: comparison with usual interstitial pneumonia 129
Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy 129
20 years of experience with tumour necrosis factor inhibitors: what have we learned? 128
A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: A EUSTAR prospective study 126
A Flow Cytometric Study of the Propidium Iodide Staining Kinetics of Human-leukocytes and Its Relationship With Chromatin Structure 126
Localized and systemic forms of scleroderma in adults and children. 125
Cytokinetic changes in the peripheral blood of leukemic patients during cytostatic therapy. VI. Effect of arabinosylcytosine. 125
Anticyclic citrullinated peptide antibodies as markers of erosive arthritis in antisynthetase syndrome. 125
Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases 125
Microcytic anemia in rheumatoid arthritis. Relationship with activity and duration of the disease and iron status. 125
Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus 125
Multidisciplinary model for hospital-territory integrated management of patient with bone fragility: Primary and secondary prevention of fractures according to severity and complexity 124
Shrinking lung syndrome in sistemic sclerosis 124
EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. 123
Analysis of the apoliporotein(a) size polymorphism in patients with systemic lupus erythematosus 123
Tocilizumab for treatment of severe covid-19 patients: Preliminary results from smatteo covid19 registry (smacore) 123
B cells in rheumatoid arthritis. 123
Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank 123
Cytomegalovirus colitis unmasking human immunodeficiency virus infection as a cause of IgA vasculitis 122
Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from EUSTAR cohort 122
Chemochine linfoidi nella sinovite reumatoide 121
Antibodies to cyclic citrullinated peptides in psoriatic arthritis. 121
Analysis of Human Myeloma Cell-population Kinetics 121
Diffuse skin reaction after changing the etanercept formulation 121
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. 120
Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). 120
CCL21 expression pattern of human secondary lymphoid organ stroma is conserved in inflammatory lesions with lymphoid neogenesis 120
[Socio-demographic aspects and therapeutic pathways in patients with rheumatoid arthritis in Italy]. 119
Soluble HLA-G in pregnancies complicated by autoimmune rheumatic diseases 119
Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital 119
A Proof-of-Concept Analysis of Plasma-Derived Exosomal microRNAs in Interstitial Pulmonary Fibrosis Secondary to Antisynthetase Syndrome 118
Interessamento cutaneo nella dermatomiosite 118
Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group 118
Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis 118
Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals 118
Reactogenicity, safety and disease flares following BNT162b2 mRNA COVID-19 vaccine in patients with chronic immune-inflammatory arthritis treated with biological and targeted synthetic disease-modifying anti-rheumatic drugs 118
TNFalpha inhibition in anti-Ro/SSA positive patients with rheumatoid arthritis: clinical and immunological effects. 117
B cell autoimmunity and bone damage in rheumatoid arthritis 117
[TNF-alpha inhibition in anti-Ro/SSA positive patients with rheumatoid arthritis: clinical and immunologic effects]. 117
ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis - A EUSTAR analysis 117
Impact of delayed diagnoses at the time of COVID-19: Increased rate of preventable bilateral blindness in giant cell arteritis 117
Association between anti-dsDNA titre increase and thymoma relapse 116
Clinical, genetic and immunologic analysis of a family affected by ozena 116
Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal 116
Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management 116
Cobalt hip prosthesis intoxication mimicking an autoimmune disease 116
Idiopathic inflammatory myopathies: Narrative review of unmet needs in clinical practice guidelines 115
A genetic variation located in the promoter region of the UPAR(CD87) gene is associated with the vascular complications of systemic sclerosis. 114
Influenza may influence rheumatoid arthritis 114
Lifestyle and dietary habits of patients with gout followed in rheumatology settings 114
Autoantibodies to heterogeneous nuclear ribonucleoproteins. 114
Mature antigen-experienced helper T cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of rheumatoid joint 114
Clinical and experimental evidences of Italian viper venom neurotoxicity. 113
Ultrasonographic and MRI characterisation of the palindromic phase of rheumatoid arthritis 113
Pulmonary nocardiosis in a patient affected by anti-MDA5-positive amyopathic dermatomyositis under immunosuppressive therapy 113
Totale 13.200
Categoria #
all - tutte 286.308
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 286.308


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.680 0 18 71 28 60 93 58 178 148 60 441 1.525
2022/20239.143 1.111 618 87 609 945 914 8 506 3.841 61 241 202
2023/20243.418 408 732 131 238 309 858 105 221 36 119 101 160
2024/20259.508 230 786 167 251 116 460 491 746 2.327 356 1.048 2.530
2025/202622.217 1.636 1.591 2.559 2.172 2.456 946 4.454 1.006 1.918 1.625 1.018 836
2026/20271.347 448 899 0 0 0 0 0 0 0 0 0 0
Totale 63.148